WO2007107161A3 - Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis - Google Patents

Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis Download PDF

Info

Publication number
WO2007107161A3
WO2007107161A3 PCT/DK2007/000143 DK2007000143W WO2007107161A3 WO 2007107161 A3 WO2007107161 A3 WO 2007107161A3 DK 2007000143 W DK2007000143 W DK 2007000143W WO 2007107161 A3 WO2007107161 A3 WO 2007107161A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
phospholipase
based drug
hydrolysis
perform
Prior art date
Application number
PCT/DK2007/000143
Other languages
French (fr)
Other versions
WO2007107161A2 (en
WO2007107161A8 (en
Inventor
Kent Joergensen
Thomas L Andresen
Original Assignee
Liplasome Pharma As
Kent Joergensen
Thomas L Andresen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma As, Kent Joergensen, Thomas L Andresen filed Critical Liplasome Pharma As
Priority to AU2007229160A priority Critical patent/AU2007229160A1/en
Priority to CA002647779A priority patent/CA2647779A1/en
Priority to JP2009500701A priority patent/JP2009530318A/en
Priority to EP07711285A priority patent/EP2004236A2/en
Publication of WO2007107161A2 publication Critical patent/WO2007107161A2/en
Publication of WO2007107161A8 publication Critical patent/WO2007107161A8/en
Publication of WO2007107161A3 publication Critical patent/WO2007107161A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a lipid-based drug delivery system for administration of anti-cancer drugs in a prodrug form, said prodrug furthermore being a substrate for extracellular phospholipase A2 to the extent that an organic radical can be hydrolytically cleaved off, resulting in an intramolecular reaction, said system comprising lipopolymers and/or glycolipids so as to present hydrophilic chains on the surface of the system. In addition, the lipid prodrug and drug carries can be used in combination with incorporated drugs. Pharmaceutical compositions comprising the drug delivery system can be used in diagnosis and targeted treatment of various disorders, e.g. cancer, infectious, and inflammatory conditions, etc., i.e. disorders and diseases associated with or resulting from increased levels of extracellular PLA2 activity in the diseased tissue.
PCT/DK2007/000143 2006-03-23 2007-03-23 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis WO2007107161A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2007229160A AU2007229160A1 (en) 2006-03-23 2007-03-23 Lipid based drug delivery systems comprising phospholipase A2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
CA002647779A CA2647779A1 (en) 2006-03-23 2007-03-23 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
JP2009500701A JP2009530318A (en) 2006-03-23 2007-03-23 Lipid-based drug delivery system containing phospholipase A2-degradable lipid that undergoes intramolecular cyclization during hydrolysis
EP07711285A EP2004236A2 (en) 2006-03-23 2007-03-23 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600411 2006-03-23
DKPA200600411 2006-03-23

Publications (3)

Publication Number Publication Date
WO2007107161A2 WO2007107161A2 (en) 2007-09-27
WO2007107161A8 WO2007107161A8 (en) 2007-11-22
WO2007107161A3 true WO2007107161A3 (en) 2008-04-10

Family

ID=38121721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/000143 WO2007107161A2 (en) 2006-03-23 2007-03-23 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis

Country Status (5)

Country Link
EP (1) EP2004236A2 (en)
JP (1) JP2009530318A (en)
AU (1) AU2007229160A1 (en)
CA (1) CA2647779A1 (en)
WO (1) WO2007107161A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
CN103338747A (en) * 2011-01-28 2013-10-02 皇家飞利浦电子股份有限公司 Carriers for the local release of hydrophilic prodrugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039831A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
EP1484332A2 (en) * 2000-02-10 2004-12-08 Liplasome Pharma A/S Lipid-based drug delivery system for administration of a drug substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039831A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
EP1484332A2 (en) * 2000-02-10 2004-12-08 Liplasome Pharma A/S Lipid-based drug delivery system for administration of a drug substance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDERSEN T L ET AL: "Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2", CURRENT DRUG DELIVERY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 2, no. 4, October 2005 (2005-10-01), pages 353 - 362, XP008088792, ISSN: 1567-2018 *

Also Published As

Publication number Publication date
AU2007229160A1 (en) 2007-09-27
JP2009530318A (en) 2009-08-27
WO2007107161A2 (en) 2007-09-27
EP2004236A2 (en) 2008-12-24
CA2647779A1 (en) 2007-09-27
WO2007107161A8 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2006048017A8 (en) Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
NZ605079A (en) Biodegradable lipids for the delivery of active agents
CY1118984T1 (en) PREPARATION OF ACTIVE, HIGHLY PHOSPHORYLATED, HUMAN LYSOSOMIC SULFATASE ENZYMES AND USES THEREOF
WO2009051837A3 (en) Vaccine nanotechnology
BRPI0607549A2 (en) pharmaceutical delivery systems for hydrophobic drugs and compositions comprising the same
WO2001058910A3 (en) Lipid-based drug delivery systems
WO2009123934A3 (en) Branched multifunctional nanoparticle conjugates and their use
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
IN2012DN00407A (en)
WO2008137758A3 (en) Amino acid lipids and uses thereof
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
NZ623450A (en) Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2007137117A3 (en) Aptamer-directed drug delivery
IN2012DN01216A (en)
WO2007100745A3 (en) Apparatus and formulations for suprachoroidal drug delivery
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
WO2011063952A8 (en) Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration
WO2012021107A8 (en) A liposomal formulation for ocular drug delivery
WO2012054500A3 (en) Compositions for drug administration
WO2007048019A3 (en) Delivery system for diagnostic and therapeutic agents
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
DK2319517T3 (en) APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION
WO2007107161A8 (en) Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07711285

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009500701

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2647779

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007229160

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007229160

Country of ref document: AU

Date of ref document: 20070323

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007711285

Country of ref document: EP